Antibodies, Assay Kits, Bap1 Antibody, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, DNA Templates, DNA Testing, E coli, EIA electrophoresis, Eif2A Antibody, Elisa Kits, Enzymes, Gsk3 Alpha, Laminin Alpha 5, Medium & Serums, Muc2 Antibody, Nedd4 Antibody, Nox1 Antibody, Panel, profiling, Pure, Purification, purified, Rabbit, Reagents, Recombinant Proteins, Rhesus, RNA, Tcf4 Antibody, Test Kits, Vector & Virus

Peripheral blood T lymphocytosis in thymoma: an insight into immunobiology

Objective: Peripheral blood T lymphocytosis (PBTL) is a uncommon, but poorly understood manifestations of thymoma, which is postulated to be linked with autoimmune/paraneoplastic manifestations resembling myasthenia gravis (MG), pure purple cell aplasia (PRCA), and so on.; extra generally encountered on this neoplasm.
Methodology: We goal to explain the flowcytometric immunophenotypic knowledge of PBTL in a 43-year-old male; 6 months after profitable completion of chemoradiotherapy (CT/RT) for a big, invasive, and metastatic sort B1 thymoma; and current a complete assessment of all such instances reported over final 42 years (N = 21) (1977-2019).
Outcome: A bigger dimension of the tumors (≥ 10 cm), presence of native invasion and/or distant metastasis, and sort B (cortical or lymphocyte wealthy) histology had been extra prone to be related to PBTL. Tumors related to MG/PRCA (N = 9/21) are likely to have decrease PBTL in comparison with these with out such manifestations; and PBTL subsided following thymectomy with or with out CT/RT. Immunophenotypic evaluation of PB revealed a CD8 + > CD4 + mature (naïve) polyclonal T cells resembling late cortical thymocytes.
Conclusion: Thymic intratumoral microenvironment would possibly affect prevalence PBTL which will have a pathophysiologic hyperlink to improvement of autoimmune manifestations. Immunophenotypic traits of peripheral blood lymphoid cells ought to be the clue for correct characterization and to keep away from a misdiagnosis of a lymphoproliferative neoplasm.

Immunobiology and pathogenesis of hepatitis B virus an infection

Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to trigger a persistent an infection, in the end resulting in cirrhosis and hepatocellular carcinoma.

Over the previous 4 many years, the essential ideas of HBV gene expression and replication in addition to the viral and host determinants governing an infection final result have been largely uncovered. Whereas HBV seems to induce little or no innate immune activation, the adaptive immune response mediates each viral clearance in addition to liver illness.

Right here, we assessment our present information on the immunobiology and pathogenesis of HBV an infection, focusing specifically on the position of CD8+ T cells and on a number of latest breakthroughs that problem present dogmas.

For instance, we now belief that HBV integration into the host genome usually serves as a related supply of hepatitis B floor antigen (HBsAg) expression throughout power an infection, presumably triggering dysfunctional T cell responses and favouring detrimental immunopathology.

Additional, the distinctive haemodynamics and anatomy of the liver – and the adjustments they ceaselessly endure throughout illness development to liver fibrosis and cirrhosis – profoundly affect T cell priming, differentiation and performance.

We additionally focus on why therapeutic approaches that restrict the intrahepatic inflammatory processes triggered by HBV-specific T cells is likely to be surprisingly useful for sufferers with power an infection.

 

Schistosomes within the Lung: Immunobiology and Alternative

Schistosome an infection is a significant trigger of worldwide morbidity, notably in sub-Saharan Africa. Nevertheless, there is no such thing as a efficient vaccine for this main uncared for tropical illness, and re-infection routinely happens after chemotherapeutic therapy. Following invasion by the pores and skin, larval schistosomula enter the circulatory system and migrate by the lung earlier than maturing to maturity within the mesenteric or urogenital vasculature.

 

Eggs launched from grownup worms can turn out to be trapped in numerous tissues, with resultant inflammatory responses resulting in hepato-splenic, intestinal, or urogenital illness – processes which were extensively studied in recent times.

 

In distinction, though lung pathology can happen in each the acute and power phases of schistosomiasis, the mechanisms underlying pulmonary illness are notably poorly understood. In power an infection, egg-mediated fibrosis and vascular destruction can result in the formation of portosystemic shunts by which eggs can embolise to the lungs, the place they’ll set off granulomatous illness.

 

Acute schistosomiasis, or Katayama syndrome, which is primarily evident in non-endemic people, happens throughout pulmonary larval migration, maturation, and preliminary egg-production, usually involving fever and a cough with an accompanying immune cell infiltrate into the lung. Importantly, lung migrating larvae will not be only a reason behind irritation and pathology however are a key goal for future vaccine design.

 

Nevertheless, vaccine efforts are hindered by a restricted understanding of what constitutes a protecting immune response to larvae. On this assessment, we discover the present understanding of pulmonary immune responses and inflammatory pathology in schistosomiasis, highlighting necessary unanswered questions and areas for future analysis.

teitell-lab
teitell-lab

Immunobiology and nanotherapeutics of extreme acute respiratory syndrome 2 (SARS-CoV-2): a present replace

The emergence of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes probably the most important world public well being problem in a century. It has reignited analysis curiosity in coronavirus.

 

  • Whereas little data is out there, analysis is at present in progress to comprehensively perceive the final biology and immune response mechanism towards SARS-CoV-2. The spike proteins (S protein) of SARS-CoV-2 carry out an important operate in viral an infection institution. ACE2 and TMPRSS2 play a pivotal position in viral entry. “
  • Upon viral entry, the launched pro-inflammatory proteins (cytokines and chemokines) trigger the migration of the T cells, monocytes, and macrophages to the an infection website.
  • IFNϒ launched by T cells initiates a loop of pro-inflammatory suggestions. The inflammatory state might additional improve with a rise in immune dysfunction liable for the an infection’s development.
  • A therapy strategy that forestalls ACE2-mediated viral entry and reduces inflammatory response is an important therapeutic intervention technique, and nanomaterials and their conjugates are promising candidates. Nanoparticles can inhibit viral entry and replication.
  • Nanomaterials have additionally discovered software in focused drug supply and in addition in growing a vaccine towards SARS-CoV-2. Right here, we briefly summarize the origin, transmission, and medical options of SARS-CoV-2. We then mentioned the immune response mechanisms of SARS-CoV-2.
  • Lastly, we additional mentioned nanotechnology’s potentials as an intervention technique towards SARS-CoV-2 an infection. All these understandings shall be essential in growing therapeutic methods towards SARS-CoV-2.

PD-1 immunobiology in glomerulonephritis and renal cell carcinoma

Background: Programmed cell loss of life protein (PD)-1 receptors and ligands on immune cells and kidney parenchymal cells assist preserve immunological homeostasis within the kidney. Dysregulated PD-1:PD-L1 binding interactions happen through the pathogenesis of glomerulopathies and renal cell carcinoma (RCC). The regulation of those molecules within the kidney is necessary to PD-1/PD-L1 immunotherapies that deal with RCC and should induce glomerulopathies as an hostile occasion.

Strategies: The expression and performance of PD-1 molecules on immune and kidney parenchymal cells had been reviewed within the wholesome kidney, PD-1 immunotherapy-induced nephrotoxicity, glomerulopathies and RCC.

Outcomes: PD-1 and/or its ligands are expressed on kidney macrophages, dendritic cells, lymphocytes, and renal proximal tubule epithelial cells. Vitamin D3, glutathione and AMP-activated protein kinase (AMPK) regulate hypoxic cell indicators concerned within the expression and performance of PD-1 molecules.

These pathways are altered in kidney illness and are linked to the manufacturing of vascular endothelial development issue, erythropoietin, adiponectin, interleukin (IL)-18, IL-23, and chemokines that bind CXCR3, CXCR4, and/or CXCR7.

These components are differentially produced in glomerulonephritis and RCC and could also be necessary biomarkers in sufferers that obtain PD-1 therapies and/or develop glomerulonephritis as an hostile occasion CONCLUSION: By evaluating the features of the PD-1 axis in glomerulopathies and RCC, we recognized related chemokines concerned within the recruitment of immune cells and distinct mediators in T cell differentiation.

 

The expression and performance of PD-1 and PD-1 ligands in diseased tissue and notably on double-negative T cells and parenchymal kidney cells wants continued exploration. The doable regulation of the PD-1 axis by vitamin D3, glutathione and/or AMPK cell indicators could also be necessary to kidney illness and the PD-1 immunotherapeutic response.

cDNA from Human Tumor Cell Line: MCF 7

C1255830 40 reactions
EUR 451.2
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

MCF 7 Membrane Lysate

XBL-10442 0.1 mg
EUR 619.8
Description: MCF 7 (Human breast Adenocarcinima) cell membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The MCF 7 (Human breast Adenocarcinima) cell was frozen in liquid nitrogen immediately after excision and then stored at -70ºC. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated MCF 7 (Human breast Adenocarcinima) cell membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal.

MCF-7 Nuclear Extract

X12002 1000 µg Ask for price

Human Mcf-7 Whole Cell Lysate

LYSATE0024 200ug
EUR 180
Description: This cell lysate is prepared from human mcf-7 using Boster's RIPA Lysis Buffer (AR0105) using a standard whole cell lysate protocol. The concentration was determined using the BCA assay process and then diluted using Dithiothreitol (DTT) and a reducing SDS sample loading buffer, heated for 5 minutes at 100˚C.

Genomic DNA from Human Tumor Cell Line: MCF 7

D1255830 100 ug
EUR 291.6
Description: Can be used for various studies in the realm of gene expression, both normal and pathological. It is an excellent control and suitable for educational purposes.

Total Protein from Human Tumor Cell Line: MCF 7

P1255830 1 mg
EUR 256.8
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Membrane Protein from Human Tumor Cell Line: MCF 7

P3255830 0.1 mg
EUR 342
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation.

Total RNA from Human Tumor Cell Line: MCF 7

R1255830-50 50 ug
EUR 232.8
Description: Can be used for various studies in the realm of gene expression and regulation, both normal and pathological. It is an excellent control and suitable for educational purposes.

Paraffin Tissue Section - Human Tumor Cell Line: MCF-7

T2255830 5 slides
EUR 308.4
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

MCF-7 Nuclear Extract (H2O2)

1642-100
EUR 248.4

Human MCF-7 (breast cancer) Cell Nuclear Extract

HCL-2016 100ug
EUR 255.6

AAV2-Luc Control Virus

AAV-320 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 2.

AAV1-Luc Control Virus

AAV-321 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 1.

AAV3-Luc Control Virus

AAV-323 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 3.

AAV4-Luc Control Virus

AAV-324 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 4.

AAV5-Luc Control Virus

AAV-325 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 5.

AAV6-Luc Control Virus

AAV-326 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 6.

Human AsPC1 / Luciferase Cell Line

SC062-Luc 2 x 106 cell/ml x 1ml
EUR 1800
Description: Firefly luciferase expression stable cell line in Human AsPC1 cells with Puromycin resistance

mouse MOPC315 / Luciferase Cell Line

SC063-Luc 2 x 106 cell/ml x 1ml
EUR 2670
Description: Firefly luciferase expression stable cell line in mouse MOPC315 cells with Puromycin resistance

MCF-7 Whole Cell Lysate (Human breast adenocarcinoma cells)

MCF7-100 100 ug
EUR 196.8

MCF-7 Whole Cell Lysate (Human breast adenocarcinoma cells)

MCF7-50 50 ug
EUR 153.6

A549 / Luciferase (Puromycin) stable cell line

SC043-Luc 2 x 106 cell/ml x 1ml
EUR 1104
Description: Luciferase (firefry) expression stable cell line in A549 human cancer cell line with Puromycin marker.

MCF-7 Human breast cancer, noninvasive cell line: >1x10^10 frozen exosomes

EXOP-100A-1 50 ug
EUR 560.4

Human PANC-1 / Luciferase (Puro) Cell Line

SC068-Luc 2 x 106 cell/ml x 1ml
EUR 2670
Description: Firefly luciferase expression stable cell line in Human PANC-1 cells with Puromycin resistance

MCF-10A

C0006015 One Frozen vial
EUR 560.4

Human MCF-7 (breast cancer) Whole Cell Lysate, Hydrogen Peroxide Stimulated

HCL-2014 100ug
EUR 255.6

293AD Cell Line

AD-100 1 vial
EUR 553.2
Description: The 293AD Cell Line is derived from the parental 293 cells but selected for attributes that increase adenovirus production, including firmer attachment and larger surface area.

293AAV Cell Line

AAV-100 1 vial
EUR 609.6
Description: The 293AAV Cell Line is derived from the parental 293 cells but selected for attributes that increase AAV production, including firmer attachment and larger surface area.

293LTV Cell Line

LTV-100 1 vial
EUR 609.6
Description: The 293LTV Cell Line is derived from the parental 293 cells but selected for attributes that increase lentiviral production, including fimrer attachment and larger surface area.

293RTV Cell Line

RV-100 1 vial
EUR 609.6
Description: The 293RTV Cell Line is derived from the parental 293 cells but selected for attributes that increase retroviral production, including fimrer attachment and larger surface area.

293/GFP Cell Line

AKR-200 1 vial
EUR 686.4
Description: 293/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

T47D/GFP Cell Line

AKR-208 1 vial
EUR 686.4
Description: T47D/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

A549/GFP Cell Line

AKR-209 1 vial
EUR 686.4
Description: A549/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

HeLa/GFP Cell Line

AKR-213 1 vial
EUR 686.4
Description: HeLa/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/GFP Cell Line

AKR-214 1 vial
EUR 686.4
Description: NIH3T3/GFP Cell Line stably expresses GFP and otherwise exhibits the same characteristics of the parental cell line.

NIH3T3/Cas9 Cell Line

AKR-5104 1 vial
EUR 686.4

293/Cas9 Cell Line

AKR-5110 1 vial
EUR 686.4

HeLa/Cas9 Cell Line

AKR-5111 1 vial
EUR 686.4

pT7- Luc

PVT10670 2 ug
EUR 361.2

pSBE- Luc

PVT10816 2 ug
EUR 361.2

pTRE3G- LUC

PVT10818 2 ug
EUR 361.2

pAP1- Luc

PVT10819 2 ug
EUR 361.2

pHSE- Luc

PVT10820 2 ug
EUR 319.2

pGRE- luc

PVT10821 2 ug
EUR 319.2

pCRE- Luc

PVT10825 2 ug
EUR 361.2

pViperin- Luc

PVT10826 2 ug
EUR 361.2

pTA- Luc

PVT10827 2 ug
EUR 361.2

pTAL- Luc

PVT10829 2 ug
EUR 361.2

pIRF3- Luc

PVT10830 2 ug
EUR 361.2

p53- Luc

PVT10836 2 ug
EUR 319.2

pBV-Luc

PVT12245 2 ug
EUR 843.6

pMR-Luc

PVT14074 2 ug
EUR 843.6

Anti-Cytokeratin 7

DB051RTU-7 7 ml
EUR 244.8
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

NF-kB/293/GFP-Luc Transcriptional Reporter Cell Line

TR860A-1 >2 x 10^6 cells
EUR 3915.6

OVCAR-5/RFP Cell Line

AKR-254 1 vial
EUR 686.4
Description: OVCAR-5/RFP Cell Line stably expresses RFP and otherwise exhibits the same characteristics of the parental cell line.

Recombinant Human Galectin-7

7-00442 2µg Ask for price

Recombinant Human Galectin-7

7-00443 10µg Ask for price

Recombinant Human Galectin-7

7-00444 1mg Ask for price

Recombinant Human Interleukin-7

7-00895 2µg Ask for price

Recombinant Human Interleukin-7

7-00896 10µg Ask for price

Recombinant Human Interleukin-7

7-00897 1mg Ask for price

Recombinant Mouse Interleukin-7

7-00904 2µg Ask for price

Recombinant Mouse Interleukin-7

7-00905 10µg Ask for price

Recombinant Mouse Interleukin-7

7-00906 1mg Ask for price

Recombinant Human Kallikrein-7

7-03034 2µg Ask for price

Recombinant Human Kallikrein-7

7-03035 10µg Ask for price

Recombinant Human Kallikrein-7

7-03036 100µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03478 5µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03479 20µg Ask for price

Recombinant ProMatrix Metalloproteinase-7

7-03480 1mg Ask for price

Individual Reaction Mix 7

G065-7 200 reactions
EUR 200.4

pUC57-Tac-Luc

PVT18215 2 ug
EUR 309.6

p21-Luc Plasmid

PVTB00035-2c 2 ug
EUR 427.2

IgK- IFN- luc

PVT10425 2 ug
EUR 319.2

pNFAT- TA- Luc

PVT10808 2 ug
EUR 319.2

pE2F- TA- Luc

PVT10809 2 ug
EUR 319.2

pISRE- TA- Luc

PVT10810 2 ug
EUR 319.2

pGAS- TA- Luc

PVT10811 2 ug
EUR 319.2

pP53- TA- luc

PVT10814 2 ug
EUR 361.2

pStat3- TA- luc

PVT10815 2 ug
EUR 361.2

pHes1 (2.5k)- Luc

PVT10832 2 ug
EUR 319.2

pHes1 (467)- luc

PVT10833 2 ug
EUR 319.2

pNF-kB-Luc

PVT1322 2 ug
EUR 390

pGL3-ELAM-Luc

PVT14533 2 ug
EUR 718.8

proE-cad178-Luc

PVT14614 2 ug
EUR 718.8

pSynSRE-T-Luc

PVT14626 2 ug
EUR 843.6

Recombinant Human Interleukin-7, Saccharomyces

7-00898 2µg Ask for price

Recombinant Human Interleukin-7, Saccharomyces

7-00899 10µg Ask for price

Recombinant Human Interleukin-7, Saccharomyces

7-00900 1mg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03154 5µg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03155 20µg Ask for price

Recombinant Human Matrix Metalloproteinase-7

7-03156 1mg Ask for price

Lung Lysate (7 Days Old)

1402-7 0.1 mg
EUR 229.2
Description: Lung tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Brain Lysate (7 Days Old)

1403-7 0.1 mg
EUR 229.2
Description: Brain tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Liver Lysate (7 Days Old)

1404-7 0.1 mg
EUR 229.2
Description: Liver tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Kidney Lysate (7 Days Old)

1405-7 0.1 mg
EUR 229.2
Description: Kidney tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Spleen Lysate (7 Days Old)

1406-7 0.1 mg
EUR 229.2
Description: Spleen tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Thymus Lysate (7 Days Old)

1409-7 0.1 mg
EUR 229.2
Description: Thymus tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Stomach Lysate (7 Day Old)

1415-7 0.1 mg
EUR 229.2
Description: Stomach tissue lysate (7 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.

Skin Lysate (7 Days Old)

1419-7 0.1 mg
EUR 229.2
Description: Skin tissue lysate (7 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.